Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Apr 9 2018

Dantrolene

  • Snapshot
    • A 31-year-old woman with a medical history of schizophrenia is brought to the emergency department by her husband due to agitation, confusion, and delirium. Her temperature is 104°F (40°C), blood pressure is 162/108 mmHg, pulse is 110/min, and respirations are 31/min. On physical examination, she is diaphoretic, with generalized muscular rigidity. Laboratory testing is significant for a creatine kinase level of 4,680 IU/L. Her antipsychotic is removed, and supportive care is initiated. She is started on dantrolene for management of neuroleptic malignant syndrome.
  • Introduction
    • Mechanism of action
      • blocks ryanodine receptors
        • decreases excitation-contraction coupling
        • decreases Ca2+ release from the sarcoplasmic reticulum in skeletal muscle
    • Clinical use
      • malignant hyperthermia
        • hypermetabolic crisis secondary to inhaled anesthetic use (e.g., halothane) or succinylcholine
          • patients have a genetic abnormality in ryanodine or dihydropyridine receptors, a skeletal muscle protein
            • results in excessive Ca2+ release from the sarcoplasmic reticulum
      • neuroleptic malignant syndrome (NMS)
        • medical emergency secondary to neuroleptic use (e.g., antipsychotics)
          • characterized by
            • hyperthermia
            • mental status change
            • rigidity
            • autonomic dysfunction
Card
1 of 0
Question
1 of 1
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options